Similarly, modulation of TAM function via TREM2 (Triggering Receptor Expressed On Myeloid Cells 2) inhibition (11) or small-molecule inhibitors of phosphatidylinositol 3-kinase γ (PI3Kγ) also relies on combination with CPI to demonstrate tumor growth regressions in preclinical models (12). The gene discussed is TREM2; the disease is neoplasm.